Lawrence Park, AM, MD presented to the U.S. Food and Drug Administration Neurological Devices Panel examining the reclassification of electroconvulsive therapy (ECT) devices on January 27, 2011. These are his remarks describing a research literature review...
Tags: adverse events,adverse reaction,anesthetic agents,benefit profile,cardiovascular complications,device malfunction,food and drug administration,lawrence park,mitigating factors,neurological devices,neuromuscular blocking agents,physical trauma,public record,pulmonary complications,reclassification,regulatory controls,research literature,seizures,skin burns,substantial risks
